Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://www.evaluatepharma.com/Universal/View.aspx?type=Entity&entityType=Product&id=53577&lType=modData&componentID=1002
Product Name Information
Product: ELI-216
Generic Name: naloxone hydrochloride; oxycodone hydrochloride
Therapeutic Subcategory: Narcotic analgesics
Clinical Trial Coverage: No. of Trials involving Product
Trial Count
ELI-216 23
A non-final office action is an Office action letter that raises new issues and usually is the first phase of the examination process. An examining attorney will issue a non-final Office action after reviewing the application for the first time. If a new issue arises after the applicant responds to the first non-final Office action, the examining attorney will issue another non-final Office action that sets forth the new issue(s) and continues any that remain outstanding. Applicants must respond to non-final Office action letters within 6 months from the date they are issued to avoid abandonment of the application.
http://itlaw.wikia.com/wiki/Non-final_office_action
It’s interesting to me that as someone who worked on Wall Street for 25 years the disparity in valuation between companies like Elite and other companies involved in development of abuse-resistant products like Pain Therapeutics, Acura, what it says to me is that, the investment community doesn't really believe us yet, but these products are going to be real. Well, there is lot of people in this company including myself and Chris and Carter, and our Chief Scientific Officer who have been paid a significant amount of stock because we do believe that. And that market has developed in a way enormously to our advantage, and we think we have a technology that is in a lot of ways superior to approaches that other companies are taking.
At this point at least one of those products is reaching the point where we expect it will go into clinical trials (in the) relatively near future.
Elite Pharmaceuticals' CEO Discusses F3Q13 Results - Earnings Call Transcript
http://seekingalpha.com/article/1203841-elite-pharmaceuticals-ceo-discusses-f3q13-results-earnings-call-transcript?source=email_rt_article_readmore
Is the ELTP/Precision Dose-Tagi agreement now "complete"? More milestone payments due upon shipment of Naltrexone and Phentermine 15/30. Will Elite look to expand it's agreement with PD/Tagi now?
four (maybe five?) products:
1) Naltrexone 50mg
2) Phentermine 37.5mg
3) Phentermine 15/30mg (count as two products?)
4) Hyromorphone HCL 8mg
http://www.news-medical.net/news/20100917/Elite-Pharmaceuticals-signs-agreements-with-Precision-Dose-for-four-generic-products.aspx
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the signing of a license agreement and a manufacturing and supply agreement (together the "Agreements") with Precision Dose, Inc. (Precision Dose) which has a wholly owned subsidiary, TAGI Pharma, Inc. ("TAGI Pharma"), which will distribute the products covered by the agreement. Pursuant to the License Agreement, TAGI Pharma will market and sell four Elite generic products (the "Products") in the United States, Puerto Rico and Canada. Elite will receive a license fee and milestone payments and Elite will manufacture the Products. The license fee will be computed as a percentage of the gross profit, as defined in the License Agreement, earned by TAGI Pharma as a result of sales of the products. The license fee is payable monthly for the term of the License Agreement. The milestone payments will be paid in 6 installments. The first installment was paid upon execution of the License Agreement and the remaining installments are to be paid upon FDA approval and initial shipment of the products to Precision Dose. Two of the Products, hydromorphone hydrochloride, 8 mg, and naltrexone hydrochloride, 50 mg, are approved products recently purchased by Elite and currently being transferred to Elite. Collectively, the brand products and their generic equivalents had total annual sales of approximately $120 million in 2009.
NOTE 4 - INVENTORIES
Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost (first-in, first-out basis) or market (net realizable value), and summarized as follows:
December 31, 2012.......... March 31, 2012
Raw Materials 547,455.......... 304,882
Work-in-Process 436,976.......... —
Finished Goods — —
Total Inventory 984,431.......... 304,482
I am disappointed in the revenue. I was hoping for $803,000
Quarter ending 9/30 was 634k. This is just a 5% increase.
However the loss from operations was greatly narrowed from -$515,000 to -$274,000. I was hoping for -$280,000 so this is even better.
Cost of revenue went WAY down.
I think the NJEDA funds + milestone $ + organic growth just about assures CFP in fiscal 4th quarter ending 3/31/13. But it's a long time between conference calls. After 2/19's call no call til late June/early July!
I'm going with
1) Loss of $280,000
2) Revenue of $803,000 (assuming 10% growth of existing products + phendimetrazine...which i know I probably spelled wrong!)
While we wait for the 10Q. How about everybody making their guess on:
1) Total operating income (or loss) (last was $515,000 loss)
2) Total Revenue (last was $635,000)
Yup I sold my flip shares on 2/6. If someone would like to sell me shares my re-buy order is waiting. I flip 20% of my shares. I am holding the rest. Is that a crime? Am I the only one doing this? Hardly.
In my opinion the pattern seems to indicate the PPS goes down during the windows indicated. But ELTP's PPS can do just about anything. PCF in today's 10Q could give it a very nice bump.
You may have looked at it backwards!
Volume is not very heavy at all. Average I'd say.
Earnings won't come out til later this week. Heck they have not even announced when the earnings will come out or when the CC will be.
Remain calm.
I haven't given up so much as I am not counting on it.
Helo's post here will give you some background:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83525929&txt2find=ecr
It's still possible, but the chances are less than 50% in my opinion. I prefer to be conservative w/ the estimates in the spreadsheet.
If anyone has heard anything new I'd love to hear it.
Dr. L
Nothing to see here.
As an example: http://www.sec.gov/Archives/edgar/data/320193/000000000011049720/filename1.pdf
Your point is what?
$3.051 million
so what? Name three stocks trading for less than .10 that have positive working capital.
Thanks for letting us know.
Spuds...Nothing to see here...Ihub has done this several times...but let me know if the good folks at Guggenheim say otherwise.
My email today w/ Dianne:
==========================================
Dianne Will
2:14 PM (0 minutes ago)
to me
No, I cannot.
I don’t know why these filings show up on iHub under ELTP.
As far as I can tell, not one of these filings has anything to do with ELTP.
This is not showing up under ELTP on SEC filing websites.
Dianne.
Dianne Will
Investor Relations for Elite Pharmaceuticals
phone: (518) 398-6222
dianne@elitepharma.com
This communications and any files transmitted with it contain information that is confidential and may be privileged and exempt from disclosure under applicable law. It is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient, you are hereby notified that any use, dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender. Thank you your cooperation.
From:
Sent: Tuesday, February 05, 2013 1:57 PM
To: Dianne Will
Subject: Designate a New Effective Date for a Post-effective Amendment Previously Filed Pursuant to Rule 485(a) (485bxt)
Dianne:
Can you shed light on this?
http://ih.advfn.com/p.php?pid=nmona&article=56004005
Thanks as always!
Well, I am guilty of same..
Mine was from Wikipedia too.
In the stock market, market price per share does not correspond to the equity per share calculated in the accounting statements. Stock valuations, which are often much higher, are based on other considerations related to the business' operating cash flow, profits and future prospects; some factors are derived from the accounting statements.
I do, but I keep my posting to a minimum.
Our Current Product Line:
GaviLyte – N AA rated generic alternative to NuLYTELY®
GaviLyte – G AA rated generic alternative to GoLYTELY® “first-to-market” generic!
GaviLyte – C AA rated generic alternative to Colyte®
Nifedipine 10mg Soft Gel Capsule AB rated generic to Procardia®
GaviLAX AA rated generic alternative to the OTC version of MiraLAX®
Orphenadrine Citrate 100mg ER Tablet AB rated generic version of Norflex®
Mesalamine Rectal Suspension Enema AB rated generic version of Rowasa®
Phenelzine Sulfate 15mg Tablets, USP AB rated generic of Nardil®
Vested means that the options are now his to do what he pleases with. He "owns" them. Often employees are given options but there is a vesting period or schedule. In this case Chris Dick was awarded 200,000 options with a vesting schedule of 1/3 every year for three years. Until those shares were vested he couldn't sell or transfer them.
The Al Frank thing is an error. I don't think it has anything to do with Elite. Much like the 497 filing we saw from Goldman Saks.
1. As previously reported, 200,000 options were issued to the reporting person on January 18, 2010 with 66,667 options vesting January 18, 2011 and 66,667 options vesting January 18, 2012. This report is filed soley to disclose that an additional 66,666 options vested January 18, 2013.
Thank you Tangerine for elucidating our path up the mountain of greatness.
I'd loan them a $1,000,000 @ 10% interest for 6 months. Link that.
Let me help...
Bontril PDM and its generic equivalents had total U.S. sales of approximately $3.5 million for the twelve months ending September 2012 based on IMS Health Data. Elite will be compensated at an agreed upon price for the manufacturing and packaging of the product.
http://globenewswire.com/news-release/2012/11/15/505442/10012673/en/Elite-Pharmaceuticals-Announces-First-Shipment-of-Generic-Phendimetrazine-Tablet-Product.html
Also looks like they are having a hard time finding a seller. Telling.
Has anyone contacted HITK/ECR lately for a Lodrane 24 update?
Another question. Did Elite ask Novel or vice versa?
Elite paid the interest on preferred shares with common shares. Once the preferred are all converted the dilution that occurred as a result of paying the interest w/ common shares will cease.
It's a trade-off. Short term pain/dilution so Elite can rid themselves of interest payments on preferred shares and receive money for the warrant conversions which will bring money to fund operations and studies etc. This should come as no surprise to anyone. It is exactly what Elite said they were going to do.
Just a note a got from IR way back when. Thought it might be helpful:
As of June 24, 2011, the total shares of Common Stock issued and outstanding and reserved for issuance upon the exercise of outstanding warrants, options, and the conversion of outstanding shares of preferred stock totaled 624,583,351 shares, including:
• 243,363,531 shares of Common Stock;
• 155,625,048 shares reserved for issuance pursuant to warrants to purchase Common Stock;
• 1,900,000 shares reserved for issuance pursuant to options to purchase Common Stock;
• 127,994,772 shares reserved for issuance upon the conversion of shares of our outstanding series of preferred stock; and
• 96,000,000 shares of Common Stock reserved for issuance pursuant to warrants issuable upon the attainment of milestones under certain agreements to which the Company is a party.
It is important to note IF the warrants are exercised, many of the warrants would result in money coming into the company.
Off to the races again...
It appears, after reviewing with IR, that this is not the case. The OS Share count is unchanged. Appears to be a math error on the 13g.